Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

Condition(s) studied

Investigational drug(s) / intervention(s)

Hormone replacement therapy: Perioperative Hydrocortisone Reduction Therapy

Placebo: Perioperative placebo Reduction Therapy

Study summary

The goal of this clinical trial is to assess the need for hydrocortisone replacement therapy during the perioperative period for large pituitary neuroendocrine tumors. The main questions it aims to answer are:

• Does hydrocortisone replacement therapy reduce the incidence of adrenal insufficiency in participants? Researchers will compare hydrocortisone to a placebo (a look-alike substance that contains no drug) to see if hydrocortisone works to reduce the incidence of adrenal insufficiency.

Participants will:

* Take or intravenous infusion drug hydrocortisone or a placebo every day for 2 weeks
* Visit the clinic three months after surgery for checkups and tests
* Keep a diary of their symptoms

Eligibility

Primary outcome measure(s)

• The incidence of adrenal insufficiency on the first or second day after surgery — the first or second day after surgery

Trial sites (1)

More Beijing Tiantan Hospital trials in China

Other trials for the same condition